顺铂、紫杉醇在复治非小细胞肺癌中的近期疗效观察

Efficacy of refractory non small cell lung cancer Patients treated with taxel and cisplatin

摘要: 目的：为了寻找非小细胞肺癌的有效治疗方法。方法：本组研究对21例对CAP、EP、NVBP、VDSP等方案耐药的非小细胞肺癌患者，采用顺铂、紫杉醇治疗。经2~3个周期治疗，进行疗效和毒副作用评价。结果：按照WHO标准，总有效率(CR+PR)为35.0%(7/20)。7例有效者均为PR，主要毒副作用为白细胞和血小板下降，脱发、肌肉/关节疼痛，Ⅲ-Ⅳ级白细胞和血小板下降并不多见，毒副作用可以耐受。结论：表明本方案对耐药性NSCLC仍然有效，可以作为二线方案应用。

Abstract: In order to search the effectiveness of Taxel+Cisplatin in patients with non small cell lung cancer (NSCLC),from May 1995 to November 1997,21 cases of NSCLC patients were treated with the combination regimen of taxel and cisplatin.All patients were resistant to several kinds of chemotherapeutic protocols such as CAP,EP,NVB P or VDS P.After two courses of treatment,their efficiency and toxicity were evaluated according to the WHO's criteria,the ovreall response rate(CR+PR)was 35 0%(7/20)with no CR and seven PR.The major toxicity were descent WBC and platelet counts,diarrhea,myalgia/arthralgia.However,Ⅲ Ⅳ grade of neutropenia and thrombocytopenia were rare observed,and most of them were tolerable.We think this protocol is safe and effective for resistant NSCLC patients.